OBN Appoints CEO
This article was originally published in Scrip
OBN, the membership organisation for the UK's emerging life sciences companies, has appointed John Harris CEO, replacing interim CEO Ross Sommerville. Harris is currently delivering business and export advice to UK trade and industry clients and assisting life science companies on growth strategies. Most recently, Harris was managing partner of Qube Associates and previously he was managing director of IPS Specials/Vertical Pharma Ltd., Key Organics Ltd. and Synerga Ltd.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.